β-blocker therapy of heart failure: An update

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 3, 2007, Pages 289-298

  Metra, Marco ^a   Nodari, Savina ^a   Bordonali, Tania ^a   Milani, Patrizia ^a   Fracassi, Francesco ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

blockers; Bisoprolol; Carvedilol; Heart failure; Metoprolol; Nebivolol

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CLENBUTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MOXONIDINE; NEBIVOLOL; PHOSPHOLAMBAN; PLACEBO; RENIN INHIBITOR; RYANODINE RECEPTOR; XAMOTEROL;

ACUTE HEART INFARCTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; MORTALITY; NONHUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; PHARMACODYNAMICS; PROTEIN PHOSPHORYLATION; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33847027342     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.3.289     Document Type: Review

References (77)

1. SWEDBERG K, CLELAND J, DARGIE H et al.: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. (2005) 26:1115-1140.
2. HUNT SA, ABRAHAM WT, CHIN MH et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005)112:e154-e235.
3. MANN DL: Mechanisms and models in heart failure: a combinatorial approach. Circulation (1999) 100:99-1088.
4. BRISTOW MR: β-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 101:558-569.
5. SWEDBERG K: Importance of neuroendocrine activation in chronic heart Failure. Impact on treatment strategies. Eur. J. Heart Fail. (2000) 2:229-233.
6. WAAGSTEIN F, HJALMARSON A, VARNAUSKAS E, WALLENTIN I: Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy. Br. Heart J. (1975) 37:1022-1036.
7. SWEDBERG K, HJALMARSON A, WAAGSTEIN F, WALLENTIN I: Beneficial effects of long-term β-blockade in congestive cardiomyopathy. Br. Heart J. (1980) 44:117-133.
8. SWEDBERG K, HJALMARSON A, WAAGSTEIN F, WALLENTIN I: Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet (1979) 1:1374-1376.
9. CHADDA K, GOLDSTEIN S, BYINGTON R, CURB JD: Effect of propanolol after acute myocardial infarction in patients with congestive heart failure. Circulation (1986) 73:503-510.
10. NORWEGIAN MULTICENTRE GROUP: Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. (1981) 304:801-807.
11. WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 342:1441-1446.
12. METRA M, NARDI M, GIUBBINI R, DEI CAS L: Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. (1994) 24:1678-1687.
13. HALL SA, CIGARROA CG, MARCOUX L, RISSER RC, GRAYBURN PA, EICHHORN EJ: Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J. Am. Coll. Cardiol. (1995) 25:1154-1161.
14. EICHHORN EJ, BRISTOW MR: Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation (1996) 94:2285-2296.
15. LECHAT P, PACKER M, CHALON S, CUCHERAT M, ARAB T, BOISSEL JP: Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 98:1184-1191.
16. LOWES BD, GILL EA, ABRAHAM WT et al.: Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am. J. Cardiol. (1999) 83:1201-1205.
17. METRA M, NODARI S, D'ALOIA A, BONTEMPI L, BOLDI E, DEI CAS L: A rationale for the use of β-blockers as standard treatment for heart failure. Am. Heart J. (2000) 139:511-521.
18. LOWES BD, GILBERT EM, ABRAHAM WT et al.: Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N. Engl. J. Med. (2002) 346:1357-1365.
19. REIKEN S, WEHRENS XH, VEST JA et al.: β-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation (2003) 107:2459-2466.
20. PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. (1996) 334:1349-1355.
21. CIBIS-II INVESTIGATORS AND COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9-13.
22. MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001-2007.
23. HJALMARSON A, GOLDSTEIN S, FAGERBERG S et al.: Effects of controlled-release metoprolol on total mortality, hospitalization and well being in patients with heart failure. JAMA (2000) 283:1295-1302.
24. PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344:1651-1658.
25. KRUM H, ROECKER EB, MOHACSI P et al.: Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 289(6):712-718.
26. DARGIE HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357:1385-1390.
27. BRISTOW M: Of phospholamban, mice, and humans with heart failure. Circulation (2001) 103:787-788.
28. MANN DL, BRISTOW MR: Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation (2005) 111:2837-2849.
29. BIRKS EJ, TANSLEY PD, HARDY J et al.: Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med. (2006) 355:1873-1884.
30. METRA M, NODARI S, D'ALOIA A et al.: β-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. (2002) 40:1248-1258.
31. LOWES BD, SIMON MA, TSVETKOVA TO, BRISTOW MR: Inotropes in the β-blocker era. Clin. Cardiol. (2000) 23(3 Suppl.):III11-6.
32. EICHHORN E, METRA M, ABRAHAM W et al.: The studies of oral enoximone therapy in advanced heart failure. J. Cardiac. Fail. (2005) 11:721.
33. THE XAMOTEROL IN SEVERE HEART FAILURE STUDY GROUP: Xamoterol in severe heart failure. Lancet (1990) 336:1-6.
34. SWEDBERG K, BRISTOW MR, COHN JN et al.: Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation (2002) 105:1797-1803.
35. COHN JN, PFEFFER MA, ROULEAU J et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur. J. Heart Fail. (2003) 5(5):659-667.
36. β-BLOCKER EVALUATION Of SURVIVAL TRIAL INVESTIGATORS: A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. (2001) 344:1659-1667.
37. ANDREKA P, AIYAR N, OLSON LC et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation (2002) 105:2429-2434.
38. MAACK C, BOHM M, VLASKIN L et al.: Partial agonist activity of bucindolol is dependent on the activation state of the human β1-adrenergic receptor. Circulation (2003) 108:348-353.
39. HERSHBERGER RE, WYNN JR, SUNDBERG L, BRISTOW MR: Mechanism of action of bucindolol in human ventricular myocardium. J. Cardiovasc. Pharmacol. (1990) 15:959-967.
40. BRIXIUS K, BUNDKIRCHEN A, BOLCK B, MEHLHORN U, SCHWINGER RH: Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol. (2001) 133:1330-1338.
41. BRISTOW MR, RODEN RL, LOWES BD, GILBERT EM, EICHHORN EJ: The role of third-generation β-blocking agents in chronic heart failure. Clin. Cardiol. (1998) 21(12 Suppl. 1):I3.
42. LIGGETT SB, MIALET PEREZ J, THANEEMIT-CHEN S et al.: A polymorphism within a conserved β(1)-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl. Acad. Sci. USA (2006) 103:11288-11293.
43. BRISTOW MR, KRAUSE-STEINRAUF H, NUZZO R et al.: Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-blocker evaluation of survival trial. Circulation (2004) 110:1437-1442.
44. POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362:7-13.
45. METRA M, TORP-PEDERSEN C, SWEDBERG K et al.: Influence of heart rate, blood pressure, and β-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur. Heart. J. (2005) 26:2259-2268.
46. METRA M, GIUBBINI R, NODARI S, BOLDI E, MODENA MG, DEI CAS L: Differential effects of β-blockes in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (2000) 102:546-551.
47. METRA M, DEI CAS L, DI LENARDA A, POOLE-WILSON PA: β-blockers in heart failure: are pharmacological differences clinically important? Heart Fail. Rev. (2004) 9:123-130.
48. METRA M, DEI CAS L, CLELAND JG: Pharmacokinetic and pharmacodynamic characteristics of β-Blockers: when differences may matter. J. Card. Fail. (2006) 12:177-181.
49. 1-receptor? A perspective on the results of the COMET trial. J. Card. Fail. (2003) 9:429-443.
50. KINDERMANN M, MAACK C, SCHALLER S et al.: Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation (2004) 109:3182-3190.
51. GONG H, SUNG H, KOCH WJ et al.: Specific β-2AR blocker ICI 118,551 actively decreases contraction through a Gi-coupled form of the β-2AR in myocytes from failing human heart. Circulation (2002) 105:2497-2503.
52. ANDERSON B, ABERG J, LINDELOW B, TANG MS, WIKSTRAND J: Dose-related effects of metoprolol on heart rate and pharmacokinetics in heart failure. J. Card. Fail. (2001) 7:311-317.
53. KUKIN ML, MANNINO MM, FREUDEBERGER RS et al.: Hemodynamic comparison of twice daily metoprolol succinate in congestive heart failure. J. Am. Coll. Cardiol. (2000) 35:45-50.
54. AQUILANTE CL, TERRA SG, SCHOFIELD RS et al.: Sustained restoration of autonomic balance with long but not short acting metoprolol in patients with heart failure. J. Cardiac Fail. (2006) 12:171-176.
55. KOMAJDA M, FOLLATH F, SWEDBERG K et al.: The EuroHeart Failure Survey program-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur. Heart J. (2003) 24:464-474.
56. NIEMINEN MS, BRUTSAERT D, DICKSTEIN K et al.: EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart J. (2006) 27:2725-2736.
57. TANDON P, MCALISTER FA, TSUYUKI RT et al.: The use of β-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch. Intern. Med. (2004) 164:769-774.
58. KRUM H, NINIO D, MACDONALD P: Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart (2000) 84:615-619.
59. LENZEN MJ, BOERSMA E, REIMER WJ et al.: Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur. Heart J. (2005) 26:2706-2713.
60. NODARI S, METRA M, DEI CAS A, DEI CAS L: Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. Eur. J. Heart Fail. (2003) 5:803-809.
61. MCMURRAY J, COHEN-SOLAL A, DIETZ R et al.: Practical recommendations for the use of ACE inhibitors, β-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur. J. Heart Fail. (2005) 7:710-721.
62. DULIN BR, HAAS SJ, ABRAHAM WT, KRUM H: Do elderly systolic heart failure patients benefit from β blockers to the same extent as the non-elderly? Meta-analysis of > 12,000 patients in large-scale clinical trials. Am. J. Cardiol. (2005) 95:896-898.
63. SIN DD, MCALISTER FA: The effects of β-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am. J. Med. (2002) 113:650-656.
64. FLATHER MD, SHIBATA MC, COATS AJ et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. (2005) 26:215-225.
65. KRUM H, HILL J, FRUHWALD F et al.: Tolerability of β-blockers in elderly patients with chronic heart failure: the COLA II study. Eur. J. Heart Fail. (2006) 8:302-307.
66. GHALI JK, PINA IL, GOTTLIEB SS et al.: Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation (2002) 105:1585-1591.
67. SIRAK TE, JELIC S, LE JEMTEL TH: Therapeutic update: non-selective β- and α-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J. Am. Coll. Cardiol. (2004) 44:497-502.
68. MAGGIONI AP, SINAGRA G, OPASICH C et al.: Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart (2003) 89:299-305.
69. METRA M, NODARI S, D'ALOIA A et al.: β blockers in heart failure: issues in the management of individual patients. Heart Fail. Rev. (1999) 4:65-77.
70. OPASICH C, BOCCANELLI A, CAFIERO M et al.: Program to improve the use of β-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study. Eur. J. Heart Fail. (2006) 8:649-657.
71. GATTIS WA, O'CONNOR CM., GALLUP DS et al.: Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure (IMPACT-HF trial). J. Am. Coll. Cardiol. (2004) 43:1534-1541.
72. CABANA MD, RAND CS, POWE NR et al.: Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA (2000) 283:1335-1337.
73. ANSARI M, SHLIPAK MG, HEIDENREICH PA et al.: Improving guideline adherence. A randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation (2003) 107:2799-2804.
74. PACKER M, LUKAS MA, TENERO DM, BAIDOO CA, GREENBERG BH; 369 STUDY GROUP: Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am. J. Cardiol. (2006) 98(7A):39-45.
75. GREENBERG BH, MEHRA M, TEERLINK JR, ORDRONNEAU P, MCCOLLUM D, GILBERT EM: COMPARE: Comparison of the Effects of Carvedilol CR and Carvedilol IR on Left Ventricular Ejection Fraction in Patients with Heart Failure. Am. J. Cardiol. (2006) 98(7A):53-59.
76. ERDOGAN D, GULLU H, CALISKAN M et al.: Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart (2006) [Epub ahead of print].
77. KIM H, PENNISI PA, GAVRILOVA O et al.: Effect of adipocyte β3-adrenergic receptor activation on the Type 2 diabetic MKR mice. Am. J. Physiol. Endocrinol Metab. (2006) 290:E1227-E1236.